Related Experiment Video
Updated: Jun 15, 2026

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
Proinsulin C-peptide prevents type-1 diabetes-induced decrease of renal Na+-K+-ATPase alpha1-subunit in rats
Lina Nordquist1, Kohei Shimada, Tatsuya Ishii
1Laboratory of Biochemistry, Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
Aims/Hypothesis:
C-peptide reduces renal damage in diabetic patients and experimental animal models. In vitro studies suggest that the renal effects of C-peptide may, in part, be explained by stimulation of Na(+)/K(+)-ATPase activity. However, the responses of Na(+)/K(+)-ATPase expression in the kidney of diabetic animals to C-peptide administration remain unclear. The aim of this study was to clarify the responses.
Methods:
Type 1 diabetic rats were produced by injecting streptozotocin (STZ), and some of the rats were treated with either C-peptide or insulin by the aid of an osmotic pump for 1 week. The mRNA expression and immunohistochemical localization of Na(+)/K(+)-ATPase alpha1-, alpha2- and beta3-subunits were investigated in the kidney of these rats.
Results:
Na(+)/K(+)-ATPase alpha1-subunit was abundantly expressed in the medullary collecting ducts of control animals, but the expression was markedly decreased in the diabetic state with concomitant decrease in its mRNA expression. Similar decreases were observed in the insulin-treated diabetic rats, whereas in the C-peptide-treated diabetic rats, there was no reduction in the alpha1-expression. The beta3-subunit was expressed in podocytes and parietal cells in the glomeruli, vascular endothelial cells, and cortical collecting ducts, but lesser signals were observed in the proximal and distal tubules. However, the beta3-subunit did not appear to be affected by the diabetic state.
Conclusions:
Diabetes selectively reduced Na(+)/K(+)-ATPase alpha1-subunit expression and abundance. Chronic administration of C-peptide prevented this decrease. This implies a role for C-peptide in the long-term regulation of Na(+)/K(+)-ATPase function.
Insights
C-peptide prevents diabetes-induced reduction in kidney Na(+)/K(+)-ATPase alpha1-subunit expression. This suggests C-peptide plays a role in maintaining kidney function during diabetes.
Area of Science:
- Nephrology
- Endocrinology
- Molecular Biology
Background:
- Diabetic nephropathy is a major complication of diabetes mellitus.
- C-peptide has shown renoprotective effects in diabetic models.
- The mechanism may involve modulation of renal Na(+)/K(+)-ATPase activity.
Purpose of the Study:
- To investigate the effect of C-peptide on Na(+)/K(+)-ATPase expression in the kidneys of diabetic rats.
- To clarify the role of C-peptide in regulating renal Na(+)/K(+)-ATPase in diabetes.
Main Methods:
- Type 1 diabetes was induced in rats using streptozotocin (STZ).
- Diabetic rats were treated with C-peptide or insulin for one week.
- Kidney expression of Na(+)/K(+)-ATPase alpha1, alpha2, and beta3 subunits was analyzed using mRNA and immunohistochemistry.
Main Results:
- Diabetes significantly decreased Na(+)/K(+)-ATPase alpha1-subunit mRNA and protein expression in the renal medulla.
- Insulin treatment did not prevent the decrease in alpha1-subunit expression.
- C-peptide treatment prevented the diabetes-induced reduction in Na(+)/K(+)-ATPase alpha1-subunit expression.
- Na(+)/K(+)-ATPase beta3-subunit expression was not significantly affected by diabetes or treatments.
Conclusions:
- Diabetes selectively downregulates Na(+)/K(+)-ATPase alpha1-subunit expression in the kidney.
- C-peptide administration preserves Na(+)/K(+)-ATPase alpha1-subunit expression in diabetic rats.
- C-peptide may have a long-term protective role in regulating renal Na(+)/K(+)-ATPase function during diabetes.
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Type I Diabetes II: Pathophysiology
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Type I Diabetes I: Introduction
